Share-based Payment Arrangement, Expense of Black Diamond Therapeutics, Inc. from 31 Dec 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Black Diamond Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2018 to 30 Sep 2025.
  • Black Diamond Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,739,000, a 13% decline year-over-year.
  • Black Diamond Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $6,852,000, a 35% decline year-over-year.
  • Black Diamond Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $10,627,000, a 11% increase from 2023.
  • Black Diamond Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $9,604,000, a 21% decline from 2022.
  • Black Diamond Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $12,197,000, a 13% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Black Diamond Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $6,852,000 $1,739,000 -$253,000 -13% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $7,105,000 $1,777,000 -$3,509,000 -66% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $10,614,000 $1,700,000 -$13,000 -0.76% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $10,627,000 $1,636,000 +$100,000 +6.5% 01 Oct 2024 31 Dec 2024 10-K 06 Mar 2025 2024 FY
Q3 2024 $10,527,000 $1,992,000 -$759,000 -28% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $11,286,000 $5,286,000 +$2,640,000 +100% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $8,646,000 $1,713,000 -$958,000 -36% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $9,604,000 $1,536,000 -$1,370,000 -47% 01 Oct 2023 31 Dec 2023 10-K 06 Mar 2025 2024 FY
Q3 2023 $10,974,000 $2,751,000 +$87,000 +3.3% 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $10,887,000 $2,646,000 -$606,000 -19% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $11,493,000 $2,671,000 -$704,000 -21% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $12,197,000 $2,906,000 -$470,000 -14% 01 Oct 2022 31 Dec 2022 10-K 12 Mar 2024 2023 FY
Q3 2022 $12,667,000 $2,664,000 -$345,000 -11% 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023 2023 Q3
Q2 2022 $13,012,000 $3,252,000 -$1,306,000 -29% 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023 2023 Q2
Q1 2022 $14,318,000 $3,375,000 +$281,000 +9.1% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $14,037,000 $3,376,000 +$906,000 +37% 01 Oct 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
Q3 2021 $13,131,000 $3,009,000 +$1,010,000 +51% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $12,121,000 $4,558,000 +$3,139,000 +221% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $8,982,000 $3,094,000 +$1,217,000 +65% 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022 2022 Q1
Q4 2020 $7,765,000 $2,470,000 -$40,000 -1.6% 01 Oct 2020 31 Dec 2020 10-K 17 Mar 2022 2021 FY
Q3 2020 $7,805,000 $1,999,000 +$1,149,000 +135% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021 2021 Q3
Q2 2020 $6,656,000 $1,419,000 +$1,227,000 +639% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $5,429,000 $1,877,000 +$1,786,000 +1963% 01 Jan 2020 31 Mar 2020 10-Q 07 May 2021 2021 Q1
Q4 2019 $3,643,000 $2,510,000 01 Oct 2019 31 Dec 2019 10-K 25 Mar 2021 2020 FY
Q3 2019 $850,000 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020 2020 Q3
Q2 2019 $192,000 01 Apr 2019 30 Jun 2019 10-Q 11 Aug 2020 2020 Q2
Q1 2019 $91,000 01 Jan 2019 31 Mar 2019 10-Q 12 May 2020 2020 Q1

Black Diamond Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $10,627,000 +$1,023,000 +11% 01 Jan 2024 31 Dec 2024 10-K 06 Mar 2025 2024 FY
2023 $9,604,000 -$2,593,000 -21% 01 Jan 2023 31 Dec 2023 10-K 06 Mar 2025 2024 FY
2022 $12,197,000 -$1,840,000 -13% 01 Jan 2022 31 Dec 2022 10-K 12 Mar 2024 2023 FY
2021 $14,037,000 +$6,272,000 +81% 01 Jan 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
2020 $7,765,000 +$4,122,000 +113% 01 Jan 2020 31 Dec 2020 10-K 17 Mar 2022 2021 FY
2019 $3,643,000 +$3,580,000 +5683% 01 Jan 2019 31 Dec 2019 10-K 25 Mar 2021 2020 FY
2018 $63,000 01 Jan 2018 31 Dec 2018 10-K 24 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.